4-甲基烟酸盐酸盐 | 94015-05-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-甲基烟酸盐酸盐
• 中文别名: 4-甲基吡啶-3-羧酸盐酸盐；4-甲基吡啶-3-甲酸盐酸盐；4-甲基烟碱盐酸盐；4-甲基烟碱.盐酸盐
• 英文名称: 4-methyl-3-pyridinecarboxylic acid hydrochloride
• 英文别名: 4-methylpyridine-3-carboxylic acid hydrochloride；4-methylnicotinic acid monohydrochloride；4-methylnicotinic acid hydrochloride；4-methylnicotinic acid hydrochloride salt；4-methylpyridine-3-carboxylic acid;hydrochloride
• CAS: 94015-05-1
• 化学式: C₇H₇NO₂*ClH
• mdl: MFCD00832700
• 分子量: 173.599
• InChiKey: QNKFCIXWPNMUAH-UHFFFAOYSA-N

物化性质

• 熔点：
  241 °C
• 稳定性/保质期：
  常温常压下稳定，避免与水分和强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.27
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  51.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封储存于阴凉、干燥的库房，远离水源和氧化剂。

SDS

Name:	4-Methylnicotinic acid hydrochloride 97% Material Safety Data Sheet
Synonym:	4-Methylpyridine-3-carboxylic acid hydrochlorid
CAS:	94015-05-1

Section 1 - Chemical Product MSDS Name:4-Methylnicotinic acid hydrochloride 97% Material Safety Data Sheet
Synonym:4-Methylpyridine-3-carboxylic acid hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
94015-05-1	4-Methylnicotinic acid hydrochloride	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 94015-05-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8ClNO2
Molecular Weight: 174

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 94015-05-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methylnicotinic acid hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 94015-05-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 94015-05-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 94015-05-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基烟酸盐酸盐 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-甲基烟酸甲酯
  参考文献：
  名称：

  胆碱能药物：一系列槟榔碱衍生物中的甲基取代对毒蕈碱型乙酰胆碱受体结合的影响

  摘要：

  制备了槟榔碱，槟榔碱和一系列衍生物，它们的区别在于分子外围位置上甲基的存在与否，并测试了它们与毒蕈碱型乙酰胆碱受体的结合。在这项研究的基础上，对槟榔碱系列的毒蕈碱激动作用受严格的结构-活性关系控制，如先前在其他激动剂系列中观察到的那样。在本系列槟榔碱衍生物中，氮取代的变化很小。

  DOI：

  10.1002/jps.2600811012
• 作为产物：
  描述：

  3-(4,4-二甲基-4,5-二氢-1,3-氧唑-2-基)吡啶 在 盐酸 作用下， 反应 22.0h， 生成 4-甲基烟酸盐酸盐
  参考文献：
  名称：

  胆碱能药物：一系列槟榔碱衍生物中的甲基取代对毒蕈碱型乙酰胆碱受体结合的影响

  摘要：

  制备了槟榔碱，槟榔碱和一系列衍生物，它们的区别在于分子外围位置上甲基的存在与否，并测试了它们与毒蕈碱型乙酰胆碱受体的结合。在这项研究的基础上，对槟榔碱系列的毒蕈碱激动作用受严格的结构-活性关系控制，如先前在其他激动剂系列中观察到的那样。在本系列槟榔碱衍生物中，氮取代的变化很小。

  DOI：

  10.1002/jps.2600811012

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• Immunopotentiator agents
  申请人：Eli Lilly and Company

  公开号：US06664271B1

  公开（公告）日：2003-12-16

  Novel compounds and methods for preparing same, immunopotentiating compositions, and a method for potentiating the immune system of a host animal. The method comprises administering to the animal an effective amount of an immunopotentiating compound of Formula I or Formula II, or a physiologically acceptable salt.

  新化合物和制备方法，免疫增强组合物，以及增强宿主动物免疫系统的方法。该方法包括向动物施用公式I或公式II的免疫增强化合物或生理上可接受的盐的有效量。
• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS<br/>[FR] DÉRIVÉS DE [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE EN TANT QU'INHIBITEURS DE PDE2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018083098A1

  公开（公告）日：2018-05-11

  The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

  本发明涉及新型的[1,2,4]三唑[1,5-a]嘧啶基衍生物，作为磷酸二酯酶2（PDE2）的抑制剂。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防治疗PDE2相关疾病，如神经和精神疾病。
• Spirocyclobutyl Piperidine Derivatives
  申请人：Bernstein Peter

  公开号：US20100130477A1

  公开（公告）日：2010-05-27

  Disclosed herein is at least one spirocyclobutyl piperidine derivative, at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

  披露至少一种螺环环丁基哌啶衍生物，至少一种包含本文披露的至少一种螺环环丁基哌啶衍生物的药物组合物，以及至少一种使用本文披露的至少一种螺环环丁基哌啶衍生物治疗至少一种组胺H3受体相关状况的方法。
• Synthesis and insecticidal efficacy of pyripyropene derivatives focusing on the C-1, C-7, and C-11 positions’ substituent groups
  作者：Kimihiko Goto、Ryo Horikoshi、Masaaki Mitomi、Kazuhiko Oyama、Tomoyasu Hirose、Toshiaki Sunazuka、Satoshi Ōmura

  DOI：10.1038/s41429-018-0064-9

  日期：2018.9

  The C-1, C-7, and C-11 positions of pyripyropene A were chemically modified to improve the insecticidal activity. Some derivatives showed higher insecticidal activities against aphids than pyripyropene A. In particular, the derivative 5c, which possesses three cyclopropyl carbonyl groups at the C-1, C-7, and C-11 positions, had excellent insecticidal activity levels in field and laboratory trials.

  吡啶并戊二烯A的C-1，C-7和C-11位置经过化学修饰以提高杀虫活性。一些衍生物对蚜虫的杀虫活性高于吡啶并戊烯A。特别是，在C-1，C-7和C-11位置具有三个环丙基羰基的衍生物5c在野外和实验室均具有出色的杀虫活性。审判。